Evolving therapeutic landscape of advanced hepatocellular carcinoma
C Yang, H Zhang, L Zhang, AX Zhu… - Nature reviews …, 2023 - nature.com
Nature reviews Gastroenterology & hepatology, 2023•nature.com
Hepatocellular carcinoma (HCC) is one of the most common solid malignancies worldwide.
A large proportion of patients with HCC are diagnosed at advanced stages and are only
amenable to systemic therapies. We have witnessed the evolution of systemic therapies
from single-agent targeted therapy (sorafenib and lenvatinib) to the combination of a
checkpoint inhibitor plus targeted therapy (atezolizumab plus bevacizumab therapy).
Despite remarkable advances, only a small subset of patients can obtain durable clinical …
A large proportion of patients with HCC are diagnosed at advanced stages and are only
amenable to systemic therapies. We have witnessed the evolution of systemic therapies
from single-agent targeted therapy (sorafenib and lenvatinib) to the combination of a
checkpoint inhibitor plus targeted therapy (atezolizumab plus bevacizumab therapy).
Despite remarkable advances, only a small subset of patients can obtain durable clinical …
Abstract
Hepatocellular carcinoma (HCC) is one of the most common solid malignancies worldwide. A large proportion of patients with HCC are diagnosed at advanced stages and are only amenable to systemic therapies. We have witnessed the evolution of systemic therapies from single-agent targeted therapy (sorafenib and lenvatinib) to the combination of a checkpoint inhibitor plus targeted therapy (atezolizumab plus bevacizumab therapy). Despite remarkable advances, only a small subset of patients can obtain durable clinical benefit, and therefore substantial therapeutic challenges remain. In the past few years, emerging systemic therapies, including new molecular-targeted monotherapies (for example, donafenib), new immuno-oncology monotherapies (for example, durvalumab) and new combination therapies (for example, durvalumab plus tremelimumab), have shown encouraging results in clinical trials. In addition, many novel therapeutic approaches with the potential to offer improved treatment effects in patients with advanced HCC, such as sequential combination targeted therapy and next-generation adoptive cell therapy, have also been proposed and developed. In this Review, we summarize the latest clinical advances in the treatment of advanced HCC and discuss future perspectives that might inform the development of more effective therapeutics for advanced HCC.
nature.com
以上显示的是最相近的搜索结果。 查看全部搜索结果